Ataxin 3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ataxin-3 (ATXN3) is a deubiquitinating enzyme encoded by the ATXN3 gene located on chromosome 14q32.12. It is best known for its involvement in Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph Disease (MJD), the most common dominant ataxia worldwide.
Ataxin-3 is a multi-domain protein consisting of:
- N-terminal Josephin domain (J domain): Contains the catalytic triad (Cys14, H119, N131) for deubiquitinating activity
- Multiple polyglutamine (polyQ) tracts: The pathogenic expansion occurs in the C-terminal region
- UIMs (Ubiquitin-Interacting Motifs): Three UIMs (UIM1, UIM2, UIM3) at the C-terminus that bind ubiquitin chains
The protein has a molecular weight of approximately 42 kDa and is composed of 361 amino acids in its normal form. Pathological expansions result in 62-87 glutamine repeats, compared to 12-44 in healthy individuals.
In its normal state, Ataxin-3 functions as a:
- Deubiquitinating enzyme (DUB): Cleaves ubiquitin chains from substrate proteins, regulating protein degradation via the ubiquitin-proteasome system
- Transcriptional regulator: Interacts with transcription factors including REST and histone deacetylases
- Quality control factor: Involved in protein homeostasis, helping clear misfolded proteins
- DNA repair modulator: Associates with DNA repair complexes
SCA3 is caused by CAG trinucleotide repeat expansion in the ATXN3 gene, encoding an expanded polyglutamine tract. The disease manifests typically in adulthood (30-50 years) and is characterized by:
- Progressive cerebellar ataxia: Loss of coordination, gait disturbance, dysarthria
- Peripheral neuropathy: Sensory and motor deficits
- Eye movement abnormalities: Ophthalmoplegia, nystagmus
- Dystonia and rigidity: Movement disorders
- Cognitive impairment: Executive dysfunction in later stages
- Toxic gain-of-function: Expanded polyQ tract causes protein misfolding and aggregation
- Neuronal inclusion formation: ATXN3 aggregates sequester essential proteins
- Transcriptional dysregulation: Altered gene expression patterns
- Mitochondrial dysfunction: Energy metabolism impairment
- Autophagy disruption: Impaired protein and organelle clearance
Current therapeutic approaches for SCA3 include:
- Gene silencing: ASOs and RNAi targeting ATXN3 mRNA (clinical trials ongoing)
- Protein aggregation inhibitors: Small molecules preventing polyQ aggregation
- Neuroprotective agents: CoQ10, vitamin E, and antioxidants
- DBS therapy: Deep brain stimulation for dystonia and tremor
- Kawaguchi Y, et al. (1994). "Expansion of unstable trinucleotide CAG repeat in spinocerebellar ataxia type 3." Nature Genetics 8(3): 221-228. DOI:10.1038/ng1194-221
- Costa MDC, Paulson HL. (2012). "Towards understanding Machado-Joseph disease." Trends in Neurosciences 35(5): 291-304.
- McLoughlin HS, et al. (2022). "ASO-based reduction of mutant ataxin-3 halts disease progression in a mouse model of spinocerebellar ataxia type 3." Brain 145(2): 487-501.
The study of Ataxin 3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kawaguchi Y, et al. (1994). "Expansion of unstable trinucleotide CAG repeat in spinocerebellar ataxia type 3." Nature Genetics 8(3): 221-228. DOI:10.1038/ng1194-221
- Costa MDC, Paulson HL. (2012). "Towards understanding Machado-Joseph disease." Trends in Neurosciences 35(5): 291-304. DOI:10.1016/j.tins.2012.01.008
- McLoughlin HS, et al. (2022). "ASO-based reduction of mutant ataxin-3 halts disease progression in a mouse model of spinocerebellar ataxia type 3." Brain 145(2): 487-501. DOI:10.1093/brain/awab332
- Chai Y, et al. (2001). "Formation of polyglutamine inclusions in non-CNS tissue." Human Molecular Genetics 10(21): 2431-2445. DOI:10.1093/hmg/10.21.2431
- Winborn BJ, et al. (2008). "The deubiquitinating enzyme ataxin-3, a linker between polyglutamine diseases and the ubiquitin-proteasome system." Molecular Cell 30(5): 567-577. DOI:10.1016/j.molcel.2008.04.009